All news

8 results out of 20
04 November 2016
The PIA, via Bpifrance, invests in YposKesi beside AFM-Téléthon
AFM-Téléthon and the SPI fund, managed by Bpifrance within the framework of the Program of Investments for the Future (PIA), create YposKesi*, the 1st French pharmaceutical industrial actor dedicated to the production of gene therapy and cellular therapy drugs for the rare diseases.
18 July 2016
Gene therapy: Bpifrance participates in the initial public offering of Gensight
Bpifrance invests €14.5mn in Gensight Biologics on the occasion of its initial public offering on Euronext Paris (1), which allows the company to finance its development on the market of the orphan hereditary illnesses of the retina and of the central nervous system.
23 March 2016
Technology transfer: the foundation stone of Métallicadour center laid
On 18 March on the Aéropolis site in Bordes-Assat near Pau, SCI Métallicadour, which shareholders are UIMM Adour (51%) and Caisse des Dépôts (49%), laid the foundation stone of the building which will house Métallicadour technology transfer center.
10 November 2015
The PIA, via Bpifrance, invests in Netatmo, a specialist of connected objects
On 5 November, Netatmo, a French company and a specialist of connected objects, announced a €30mn fund raising made in particular with Fonds ambition numérique, managed by Bpifrance within the framework of the Program of investments for the future (PIA).
19 October 2015
The PIA finances the seed-stage and the acceleration of innovative companies via Bpifrance
The PIA participates in a new seed fund of €30.5mn dedicated to the innovative companies in Champagne-Ardenne, Lorraine, Nord-Pas de Calais and Picardy, Fira nord-est, and invests in the acceleration fund Breega Capital Venture One, respectively via the FNA and French Tech Accélération, managed by Bpifrance.
09 January 2015
Life sciences: Bpifrance supports Sight Again and Cellectis
Bpifrance, as an operator of the PIA, allocates €18.5mn to Sight Againt collaborative project developed by GenSight Biologics, Pixium Vision and Voir et Entendre foundation, whereas Cellectis, the main shareholder of which is Bpifrance, announces its coming IPO on the New York Stock Exchange.
18 February 2015
Bpifrance supports three biotech projects within the framework of the PIA
Bpifrance supports, within the framework of the Program of investments for the future (PIA), three projects in the field of biotechnology: Hecam (cancer research), AAVLife (gene therapy) and Algolife (nutrition & health).
18 February 2015
The PIA and Bpifrance participate in Sigfox €100mn fundraising
Fonds Ambition Numérique of the PIA, subscribed by Caisse des Dépôts and managed by Bpifrance for the State, participates in Sigfox €100mn fundraising. Bpifrance also plays a part with its Large Venture fund, beside telecommunication operators, manufacturers and financial investors.
Haut de page